ACIU vs. CDT, VERU, FHTX, EBS, QURE, ME, PBYI, ZVRA, ALDX, and HOWL
Should you be buying AC Immune stock or one of its competitors? The main competitors of AC Immune include Conduit Pharmaceuticals (CDT), Veru (VERU), Foghorn Therapeutics (FHTX), Emergent BioSolutions (EBS), uniQure (QURE), 23andMe (ME), Puma Biotechnology (PBYI), Zevra Therapeutics (ZVRA), Aldeyra Therapeutics (ALDX), and Werewolf Therapeutics (HOWL). These companies are all part of the "pharmaceutical preparations" industry.
Conduit Pharmaceuticals (NASDAQ:CDT) and AC Immune (NASDAQ:ACIU) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their earnings, community ranking, institutional ownership, valuation, risk, dividends, profitability, media sentiment and analyst recommendations.
AC Immune received 253 more outperform votes than Conduit Pharmaceuticals when rated by MarketBeat users.
AC Immune's return on equity of 0.00% beat Conduit Pharmaceuticals' return on equity.
Conduit Pharmaceuticals has higher earnings, but lower revenue than AC Immune.
3.3% of Conduit Pharmaceuticals shares are owned by institutional investors. Comparatively, 51.4% of AC Immune shares are owned by institutional investors. 23.5% of Conduit Pharmaceuticals shares are owned by company insiders. Comparatively, 4.6% of AC Immune shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.
In the previous week, AC Immune had 15 more articles in the media than Conduit Pharmaceuticals. MarketBeat recorded 16 mentions for AC Immune and 1 mentions for Conduit Pharmaceuticals. AC Immune's average media sentiment score of 1.89 beat Conduit Pharmaceuticals' score of 0.92 indicating that Conduit Pharmaceuticals is being referred to more favorably in the media.
AC Immune has a consensus target price of $16.00, indicating a potential upside of 381.93%. Given Conduit Pharmaceuticals' higher probable upside, analysts plainly believe AC Immune is more favorable than Conduit Pharmaceuticals.
Conduit Pharmaceuticals has a beta of 2.52, meaning that its stock price is 152% more volatile than the S&P 500. Comparatively, AC Immune has a beta of 1.05, meaning that its stock price is 5% more volatile than the S&P 500.
Summary
Conduit Pharmaceuticals and AC Immune tied by winning 6 of the 12 factors compared between the two stocks.
Get AC Immune News Delivered to You Automatically
Sign up to receive the latest news and ratings for ACIU and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding ACIU and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
AC Immune Competitors List
Related Companies and Tools
